Significant attenuation of macrovascular involvement by bosentan in a patient with diffuse cutaneous systemic sclerosis with multiple digital ulcers and gangrene

Modern Rheumatology

Volumn 21, Issue 5, 2011, Pages 548-552

  Ichimura, Yohei ^a   Asano, Yoshihide ^a   Hatano, Masaru ^b   Tamaki, Zenshiro ^a   Takekoshi, Tomonori ^a   Kogure, Asako ^a   Tomita, Manabu ^a   Kawashima, Tomohiko ^a   Miyazaki, Miki ^a   Taniguchi, Takashi ^a   Takahashi, Takehiro ^a   Mitsui, Hiroshi ^a   Sugaya, Makoto ^a   Yao, Atsushi ^b   Kinugawa, Koichiro ^b   Sato, Shinichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Bosentan; Digital ulcers and gangrene; Macrovascular disease; Systemic sclerosis

Indexed keywords

ARGATROBAN; BOSENTAN; PROSTAGLANDIN E1; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR;

ADULT; ANAMNESIS; ARTERY OCCLUSION; ARTICLE; CASE REPORT; DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; GANGRENE; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SKIN ULCER; SYSTEMIC SCLEROSIS; ULNAR ARTERY; VASCULARIZATION;

ANTIHYPERTENSIVE AGENTS; FEMALE; FINGERS; GANGRENE; HUMANS; MIDDLE AGED; REGIONAL BLOOD FLOW; SCLERODERMA, DIFFUSE; SKIN ULCER; SULFONAMIDES;

EID: 84855703479     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-011-0436-5     Document Type: Article

References (20)

1. Abraham DJ, Krieg T, Distler J, Distler O. Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford) 2009; 48(Suppl 3):iii3-7.
2. Hasegawa M, Nagai Y, Tamura A, Ishikawa O. Arteriographic evaluation of vascular changes of the extremities in patients with systemic sclerosis. Br J Dermatol. 2006;155:1159-64. (Pubitemid 44729989)
3. Stafford L, Englert H, Gover J, Bertouch J. Distribution of macrovascular disease in scleroderma. Ann Rheum Dis. 1998;57: 476-9. (Pubitemid 28428217)
4. Youssef P, Englert H, Bertouch J. Large vessel occlusive disease associated with CREST syndrome and scleroderma. Ann Rheum Dis. 1993;52:464-6. (Pubitemid 23209606)
5. Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al. Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004;50:3985-93. (Pubitemid 39643947)
6. Kowal-Bielecka O, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L, et al. EULAR recommendations for the treatment of systemic sclerosis: A report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009;68: 620-8.
7. Norton WL, Nardo JM. Vascular disease in progressive systemic sclerosis (scleroderma). Ann Intern Med. 1970;73:317-24.
8. Campbell PM, LeRoy EC. Pathogenesis of systemic sclerosis: A vascular hypothesis. Semin Arthritis Rheum. 1975;4:351-68.
9. D'Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). A study of fiftyeight autopsy cases and fifty-eight matched controls. Am J Med. 1969;46:428-40.
10. Ahmadi-Simab K, Hellmich B, Gross WL. Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease. Eur J Clin Invest. 2006;36(Suppl 3):44-8. (Pubitemid 44179781)
11. Cozzi F, Montisci R, Marotta H, Bobbo F, Durigon N, Ruscazio M, et al. Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases. Eur J Clin Invest. 2006;36(Suppl 3):49-53. (Pubitemid 44179782)
12. Denton CP, Pope JE, Peter HH, Gabrielli A, Boonstra A, van den Hoogen FH, et al. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis. 2008;67:1222-8.
13. McLaughlin VV. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. Eur J Clin Invest. 2006;36(Suppl 3):10-5. (Pubitemid 44179776)
14. Cambrey AD, Harrison NK, Dawes KE, Southcott AM, Black CM, du Bois RM, et al. Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro. Am J Respir Cell Mol Biol. 1994;11:439-45.
15. Yang Z, Krasnici N, Luscher TF. Endothelin-1 potentiates human smooth muscle cell growth to PDGF: Effects of ETA and ETB receptor blockade. Circulation. 1999;100:5-8. (Pubitemid 29297932)
16. Shi-Wen X, Chen Y, Denton CP, Eastwood M, Renzoni EA, Bou-Gharios G, et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell. 2004;15:2707-19. (Pubitemid 38691860)
17. Iannone F, Riccardi MT, Guiducci S, Bizzoca R, Cinelli M, Matucci-Cerinic M, et al. Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension. Ann Rheum Dis. 2008;67:1121-6.
18. Abraham D. Role of endothelin in lung fibrosis. Eur Respir Rev. 2008;17:145-50.
19. Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, Olsen I, Penny R, et al. Circulating endothelin-1 levels in systemic sclerosis subsets-a marker of fibrosis or vascular dysfunction? J Rheumatol. 1994;21:1838-44. (Pubitemid 24312644)
20. Yamane K, Miyauchi T, Suzuki N, Yuhara T, Akama T, Suzuki H, et al. Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol. 1992;19:1566-71.